腹膜透析患者高钾血症的发生率和影响因素分析  

Hyperkalemia in patients on peritoneal dialysis:incidence and risk factors

作　　者：王道艳 孙作艳 高艳丽 陈忠光 WANG Daoyan;SUN Zuoyan;GAO Yanli;CHEN Zhongguang(Department of Pharmacy,Linyi Central Hospital,Linyi,Shandong 276000,China)

机构地区：[1]临沂市中心医院药学部,山东临沂276000

出　　处：《医药前沿》2023年第26期6-8,共3页Journal of Frontiers of Medicine

摘　　要：目的:探讨腹膜透析(PD)患者高钾血症的发生情况及相关影响因素。方法:回顾性分析临沂市中心医院2019年5月—2023年5月315例腹膜透析患者的临床资料。结果:315例PD患者中102例(32.38%)患者发生过高钾血症。多因素Logistic回归结果显示,与高钾血症发生相关的独立因素包括体质指数(BMI)(OR=1.102,95%CI:1.015~1.196)、透析龄(OR=1.050,95%CI:1.024~1.076)、血磷(OR=1.909,95%CI:1.005~3.626)、使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂(ACEI/ARB)(OR=3.425,95%CI:1.784~6.575)、使用质子泵抑制剂(PPI)(OR=0.225,95%CI:0.060~0.839)。结论:PD患者高钾血症发生率高,BMI、透析龄、血磷、使用ACEI/ARB、低使用PPI是高钾血症的独立危险因素。Objective To investigate the incidence of hyperkalemia in patients on peritoneal dialysis and its risk factors.Methods This is a retrospective study that evaluated clinical data of 315 peritoneal dialysis patients from May 2019 to May 2023.Results We evaluated potassium measurements obtained from 315 patients on PD.Hyperkalemia was obtained from 102 patients(32.38%).Multivariate logistic regression showed that body mass index(BMI)(OR=1.102,95%CI:1.015~1.196),duration of PD(OR=1.050,95%CI:1.024~1.076),serum phosphorus(OR=1.909,95%CI:1.005~3.626),using angiotensin converting enzyme inhibitor or angiotensinⅡreceptor antagonist(ACEI/ARB)(OR=3.425,95%CI:1.784~6.575),using proton pump inhibitor(PPI)(OR=0.225,95%CI:0.060~0.839)were associated with hyperkalemia.Conclusions Hyperkalemia is very frequent in patients on PD.BMI,duration of PD,serum phosphorus,using ACEI/ARB,low using PPI were risk factors of hyperkalemia.

关 键 词：腹膜透析 高钾血症 质子泵抑制剂 ACEI/ARB 

分 类 号：R692[医药卫生—泌尿科学]